Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation (ADPT) is a leader in immune-driven diagnostics, pioneering NGS-based solutions for minimal residual disease detection and immune system mapping. This page serves as the definitive source for official company announcements, financial disclosures, and scientific advancements.
Investors and researchers will find curated updates including earnings reports, regulatory milestones, and partnership developments in precision medicine. Our repository ensures immediate access to press releases about clonoSEQ adoption, clinical trial collaborations, and innovations in immune medicine.
All content is rigorously verified to provide reliable insights into ADPT's strategic direction within the biotechnology sector. Bookmark this page for real-time updates on diagnostic advancements and market-moving developments.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 12:30 p.m. PT / 3:30 p.m. ET. The company focuses on leveraging the biology of the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. Adaptive has three commercial products and a robust clinical pipeline aimed at personalized medicine.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced that it will report its financial results for the fourth quarter and full year 2021 on February 15, 2022, following market close. The company will hold a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. A live audio webcast will be available on its website, with a replay accessible within 24 hours post-event.
Adaptive is focused on the adaptive immune system, developing diagnostic and therapeutic products. They have three commercial products and a strong clinical pipeline aimed at various diseases.
Adaptive Biotechnologies (ADPT) announced preliminary revenue for 2021, estimating it between $153 million and $154 million, a significant increase of approximately 56% from $98.4 million in 2020. CEO Chad Robins cited strong performance and positioned the company for sustainable growth in immune medicine and minimal residual disease (MRD) sectors. Additionally, CFO Chad Cohen will resign effective February 15, 2022, with principal accounting officer Kyle Piskel stepping in as interim CFO. Full financial results are set to be released around February 15, 2022.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. This updated presentation time reflects a change from previous announcements. Interested parties can access a live and archived webcast of the presentation on the company’s website under the 'Investors' section. The company focuses on harnessing the adaptive immune system for clinical products aimed at diagnosing and treating diseases, with three commercial products and a robust clinical pipeline.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10th, 2022, at 12:45 p.m. PT / 3:45 p.m. ET. The company aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseases. Interested parties can access a live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on developing immune-driven clinical products, with three commercial offerings and a robust pipeline addressing cancer, autoimmune conditions, and infectious diseases.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced promising data at the ASH 63rd Annual Meeting regarding its clonoSEQ Assay's ability to assess minimal residual disease (MRD) in multiple myeloma and chronic lymphocytic leukemia patients. Key findings from the MASTER trial showed that 71% of patients achieved two consecutive MRD-negative results, allowing for successful treatment discontinuation. The data supports clonoSEQ as a standard care tool, demonstrating its significance in monitoring blood cancers and potentially improving patient quality of life.
Adaptive Biotechnologies (Nasdaq: ADPT) will present over 30 abstracts at the 63rd Annual Meeting of the American Society of Hematology (ASH) from December 11-14, showcasing the effectiveness of its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancer patients. This FDA-approved assay is significant for conditions like multiple myeloma and chronic lymphocytic leukemia. The data highlights clonoSEQ's role in guiding treatment decisions, aiding in precise disease monitoring, and improving patient outcomes. The event will feature several oral and poster presentations emphasizing these findings.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that Palmetto GBA's Molecular Diagnostics Program has finalized a local coverage determination (LCD) for the clonoSEQ® assay, which detects and monitors minimal residual disease (MRD) in blood cancers. This LCD includes coverage for B-cell acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia, thereby expanding access for approximately 700,000 patients in the U.S. The clonoSEQ assay is the only FDA-cleared test for MRD assessment in these conditions and is currently available to over 240 million covered lives.
Adaptive Biotechnologies (ADPT) reported strong financial results for Q3 2021, with revenue of $39.5 million, a 50% increase year-over-year. Sequencing revenue saw a remarkable 96% growth, reaching $22.1 million. However, the company faced rising operating expenses of $95.8 million, leading to a net loss of $56.0 million, up from $36.7 million in Q3 2020. They reaffirmed their full-year revenue guidance of $148 million to $155 million, indicating a projected 54% growth compared to 2020. Cash reserves stood at $632.4 million as of September 30, 2021.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will release its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The event will be accessible via a live webcast on the company's website, with an archived replay available within 24 hours.
Adaptive focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating various diseases, including cancer and autoimmune conditions.
